Kaken Pharmaceutical Co., Ltd. (TYO:4521)
Japan flag Japan · Delayed Price · Currency is JPY
4,278.00
+73.00 (1.74%)
Feb 5, 2025, 3:30 PM JST

Kaken Pharmaceutical Company Description

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally.

The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions.

It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens.

In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia.

Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.

Kaken Pharmaceutical Co., Ltd.
Country Japan
Founded 1917
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,135
CEO Hiroyuki Horiuchi

Contact Details

Address:
28-8, Honkomagome 2-chome
Tokyo, 113-8650
Japan
Phone 81 3 5977 5007
Website kaken.co.jp

Stock Details

Ticker Symbol 4521
Exchange Tokyo Stock Exchange
Stock Type Common Stock
Fiscal Year April - March
Reporting Currency JPY
ISIN Number JP3207000005
SIC Code 2834

Key Executives

Name Position
Hiroyuki Horiuchi Chief Executive Officer